Address: No.9 Baoyuan Road,Laishan District,Yantai – Shandong Province, PRC,China
Tel: (86)535-6717618
Luye Pharma is a leading specialty pharmaceutical group in the People’s Republic of China (“PRC”) focusing on the research and development, production and sale of natural drugs , drugs with new delivery system and new drugs with other specific features. Luye Pharma is dedicated to the provision of quality medicinal products and professional services to our clients and actively engages in research and development (‘R&D’) to continuously enhance its capabilities and product portfolio.
Currently Luye Pharma’s products have an established presence in the PRC and are widely used in the fields of oncology, orthopaedics, neurology, gastroenterology, cardio vascular and hepatology. Luye Pharma’s products have access to over 3000 hospitals across the country, and leveraging on an extensive distribution network in the PRC, entering new markets, including Singapore , Malaysia , Pakistan , Vietnam, Croatia, Norway and South Korea.
Today, Luye Pharma is known to the industry as a fast emerging Chinese pharmaceutical group with strong R&D capabilities, the R&D team is well-recognized for their expertise and ability to conduct all stage research activities for new drug discovery. Luye Pharma’s ultra modern facilities in Yantai, Nanjing and Beijing are fully equipped with leading-edge technology, fully integrated and GMP/GLP certified, enabling Luye Pharma to carry out all aspects of pre-clinical research and clinical trials to full production of formulation drugs.
Luye Pharma continues to make headway towards its organizational targets. Luye Pharma will endeavor to adhere to its corporate values and mission in developing the highest potential of the company and to generate the greatest value for our shareholders and customers alike. Luye Pharma is headquartered in Singapore.
oncology, orthopaedics, neurology, gastroenterology, cardio vascular and hepatology
Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the…
What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the late 1980s that there…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into rare disease public insurance coverage across key…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences. …
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province,…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s second-largest pharma market has steadily expanded the 4+7 pilot program into…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning of 2020, the country bounced back…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six…
The latest from Chinese pharma, including domestic regulatory approval for Sinopharm’s COVID-19 vaccine, how the country’s online healthcare industry is booming in the wake of the pandemic, and news that…
The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement,…
See our Cookie Privacy Policy Here
